Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on polyunsaturated fatty acid ethyl esters with first TNF-alpha inhibitor in psoriatic arthritis
2026-526768-20-00Phase 2Authorised
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of omega-3-acid ethyl esters, adalimumab, certolizumab pegol, golimumab, infliximab and 1 more in psoriatic arthritis (PsA) (2 arms), sponsored by Fondazione Policlinico Universitario Campus Bio-Medico. Primary endpoints: Change in pain intensity at Month 6 and Minimal disease activity at Month 6. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2026-526768-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526768-20-00.